Bococizumab

From Ganfyd

Jump to: navigation, search
Bococizumab is a humanized monoclonal antibody binding proprotein directed against PCSK9 which is being studied in the SPIRE trials[1]. It spectacularly lowers LDL cholesterol[2] and was in phase 3 trials by 2016.

References